KeyBanc analyst Matthew Gillmor CFA has maintained their neutral stance on ARDT stock, giving a Hold rating on November 14.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Matthew Gillmor CFA has given his Hold rating due to a combination of factors impacting Ardent Health Partners, Inc. While the company shows potential with its unique joint venture strategy and growth opportunities, there are emerging concerns that have prompted a more cautious outlook. Specifically, uncertainties surrounding the EBITDA baseline for 2025 and downward revisions for 2026 estimates are significant. These revisions are influenced by increasing pressures from payor denials and rising professional fees, particularly in radiology, which have negatively impacted financial projections.
Despite the company’s valuation appearing deeply discounted, the uncertainty in estimates makes this less relevant. Gillmor also notes that while there are potential catalysts such as joint venture announcements and Rural Transformation funding, these are not sufficient to offset current concerns. The analyst is looking for more confidence that the issues affecting the latter half of 2025 are stabilizing and that the company’s efficiency programs are yielding results before considering a more favorable rating.
In another report released on November 14, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $10.00 price target.